Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00013806
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2001-03-29
Brief Title:
CHP677 I-Metaiodobenzylguanidine I-MIBG Therapy for Refractory Neuroblastoma a Phase II Study
Sponsor:
National Center for Research Resources NCRR
Organization:
National Center for Research Resources NCRR
Study Overview
Official Title:
CHP677 I-Metaiodobenzylguanidine I-MIBG Therapy for Refractory Neuroblastoma a Phase II Study
Status:
UNKNOWN
Status Verified Date:
2003-12
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
131I-metaiodobenzylguanidine 131I-MIBG is a norepinephrine analog that concentrates in adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma This is a dual institution Phase II study of 131I-MIBG administered at the previously defined maximum practical dose of 18 mCikg to children with relapsed or refractory neuroblastoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: